Neurimmune is a biopharmaceutical company with a strong commitment to develop immunotherapies based on recombinant human-derived monoclonal antibodies for the treatment and prevention of major neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, ALS and frontotemporal dementia.
Neurimmune will support a maximum of five ICMN2018 presenters with a travel fellowship in the amount of $500 or $1000. Fellowship awardees will be selected from the submitted abstracts by the ICMN2018 scientific committee. No additional application is necessary.
Travel fellowship winners will be contacted by email and announced on the ICMN 2018 website by mid-February 2018 and fellowships will be distributed to recipients through a reimbursement mechanism after the conference. The decision by the Scientific committee is final and cannot be appealed.
The link to the Neurimmune website is the following: www.neurimmune.com
|Renaud Bussiere||Université Côte d'Azur||France|
|Chun Hao Wong||King’s College London||United Kingdom|
|Ekaterina Pchitskaya||Peter the Great St. Petersburg Polytechnic University||Russia|
|Federica Piancone||IRCCS Milan||Italy|
|Charles Jourdan Reyes||University of Lübeck||Germany|